EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta‐Analysis of Randomized Controlled Trials With Trial Sequential Analysis

Vivek Mishra, Debabrata Dash, Aditya K Panda, Sushil Kumar Pathak iD

Helicobacter · 2024

DOI: 10.1111/hel.70006 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Helicobacter, 2024. Verfasst von Vivek Mishra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Berhampur University, Berhampur, Odisha, India. Hauptthemen laut MEDLINE: Helicobacter Infections, Probiotics, Lactobacillus, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Ramalingaswami Re-entry Fellowship, Department of Biotechnology, Government of India, DST-INSPIRE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Helicobacter pylori infection is a major global health concern and has been associated with a number of gastrointestinal disorders. Probiotics, especially Lactobacillus spp., have been suggested to have beneficial effect in managing H. pylori infection. This meta‐analysis of randomized control trials (RCTs) aimed to evaluate the effect of Lactobacillus spp. supplementation on H. pylori eradication rates and associated side effects when combined with standard therapy. Materials and Methods Relevant studies were retrieved from PubMed, Scopus, Google Scholar and the Cochrane Library. Comprehensive Meta‐Analysis (CMA) Software 4.0 was used for all the statistical analyses. TSA 0.9.5.10 Beta software was used for the trial sequential analysis (TSA). GRADEpro GDT was used to assess the certainty of evidence.

Results

An analysis of 26 selected studies showed that supplementing with Lactobacillus spp. significantly increased the rates of H. pylori eradication in per‐protocol (PP) analysis (Overall risk ratio [RR] = 1.063, p = 0.000, 95% CI of −0.21 to 2.11; adults: RR = 1.050, p = 0.005, 95% CI = −0.55 to 2.03, children: RR = 1.223, p = 0.001, 95% CI = −13.35 to 4.55). In comparison to quadruple therapy, Lactobacillus spp. supplementation to triple therapy showed significant benefit (RR: 1.124; p = 0.000, 95% CI of −0.48 to 2.61). L. reuteri supplementation indicated better efficacy (RR: 1.049; p = 0.055, 95% CI of −0.56 to 3.26) than Lactobacillus GG (RR: 0.980; p = 0.595, 95% CI of −0.69 to 1.21). The 28–30 day (RR: 1.103; p = 0.003, 95% CI of −2.14 to 4.19) and 14‐day supplementation periods (RR: 1.102; p = 0.003, 95% CI of −1.69 to 3.51) showed the most improvement. The analysis also revealed that Lactobacillus spp. significantly reduced gastrointestinal side effects: nausea/vomiting (RR: 0.566; p = 0.037, −3.11 to 1.45), diarrhea (RR: 0.324; p = 0.000, −5.46 to 0.48), and abdominal pain (RR: 0.438; p = 0.007, −5.65 to 4.22). The effect on bloating was non‐significant (RR: 0.820; p = 0.498, −4.01 to 0.96). TSA graphs validated sufficient evidence for the conclusions.

Conclusion

Lactobacillus spp. significantly enhances H. pylori eradication rates and may reduce gastrointestinal side effects when used alongside standard therapy, offering a promising adjunctive treatment option. The evidence was supported by TSA and assessed using GRADEpro, indicating a high certainty of the findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsProbioticsLactobacillusRandomized Controlled Trials as TopicHelicobacter pyloriHumansTreatment OutcomeAnti-Bacterial AgentsDietary Supplements

Stichwörter der Autor:innen

H. pyloriLactobacillus spp.eradication therapymeta‐analysisprobioticsrandomized control trials

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Biotechnology, Berhampur University, Berhampur, Odisha, India.
  • Centre of Excellence on Bioprospecting of Ethno-Pharmaceuticals of Southern Odisha, (CoE-BESO), Berhampur University, Berhampur, India.

ORCID-Profile: Sushil Kumar Pathak

Förderung

  • Ramalingaswami Re-entry Fellowship, Department of Biotechnology, Government of India
  • DST-INSPIRE

Zitieren

APA

Mishra, V., Dash, D., Panda, A. K., & Pathak, S. K. (2024). Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta‐Analysis of Randomized Controlled Trials With Trial Sequential Analysis. Helicobacter. https://doi.org/10.1111/hel.70006

Vancouver

Mishra V, Dash D, Panda AK, Pathak SK. Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta‐Analysis of Randomized Controlled Trials With Trial Sequential Analysis. Helicobacter. 2024. doi:10.1111/hel.70006

BibTeX
@article{Mishra2024,
  author = {Mishra, Vivek and Dash, Debabrata and Panda, Aditya K and Pathak, Sushil Kumar},
  title = {Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta‐Analysis of Randomized Controlled Trials With Trial Sequential Analysis},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.70006}
}
Kostenlos starten →